Disease relevance of Neurocysticercosis

• Our results are in contrast with those of most studies from countries with a low incidence of neurocysticercosis, where brain tumors, cerebrovascular disease, trauma, and alcoholism are the main causes of tardive epilepsy [1].
• Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru [2].
• BACKGROUND: Large cerebral infarction is a rare complication of neurocysticercosis [3].
• By using a monoclonal-based antigen detection enzyme-linked immunosorbent assay, we measured the levels of circulating parasite antigen in the sera of 56 patients with neurocysticercosis: 27 with calcifications only and 29 with hydrocephalus [4].
• Taenia solium taeniasis and neurocysticercosis in a Mexican rural family [5].

Psychiatry related information on Neurocysticercosis

• The main clinical manifestations of neurocysticercosis are seizures, headache, and focal neurological deficits, and it can have such sequelae as epilepsy, hydrocephalus, and dementia [6].

High impact information on Neurocysticercosis

• A diagnosis of neurocysticercosis should be considered in patients with seizures and radiologic evidence of cystic brain lesions, even in those who do not eat pork and who have not traveled to a country in which T. solium infection is endemic [7].
• Neurocysticercosis and epilepsy [8].
• Monocyte-astrocyte networks and the regulation of chemokine secretion in neurocysticercosis [9].
• CONCLUSIONS: Previous reports of favorable response to treatment of neurocysticercosis with either praziquantel or albendazole are by no means definitive and may be a reflection of the natural history of the condition [10].
• METHODS: Randomized clinical trial of treatment of patients with newly identified active neurocysticercosis with oral prednisolone alone (27 patients), praziquantel with prednisolone (54 patients), or albendazole with prednisolone (57 patients) [10].

Chemical compound and disease context of Neurocysticercosis

• Albendazole therapy for neurocysticercosis [11].
• Treatment with praziquantel for neurocysticercosis frequently induces adverse reactions due to acute destruction of parasites; these reactions are suppressed by dexamethasone therapy [12].
• Albendazole (ABZ) is a benzimidazole anthelmintic drug used in the treatment of neurocysticercosis [13].
• Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants [14].
• The recent introduction of anticysticercal drugs, an isoquinoline (praziquantel) and a benzimidazole (albendazole), has dramatically changed the medical management of neurocysticercosis [15].

Biological context of Neurocysticercosis

• Epilepsy secondary to active or inactive neurocysticercosis (NCC) is a major public health problem in Latin American countries [16].
• Solitary neurocysticercosis case caused by Asian genotype of Taenia solium confirmed by mitochondrial DNA analysis [17].
• Clinical pharmacokinetics of albendazole in patients with brain cysticercosis [18].
• The relevance of the above findings for the serology and prognosis of T. solium cysticercosis/neurocysticercosis in hospital- and field-based situations is discussed [19].
• Possible association between Taenia solium cysticercosis and cancer: increased frequency of DNA damage in peripheral lymphocytes from neurocysticercosis patients [20].

Anatomical context of Neurocysticercosis

• Surgical treatment for mesial temporal lobe epilepsy in the presence of massive calcified neurocysticercosis [21].
• Antigens were detected in cerebrospinal fluid (CSF) samples from patients with neurocysticercosis (NC) by enzyme-linked immunosorbent assay (ELISA) using polyclonal sera of rabbit anti-Taenia solium cysticerci (anti-Tso) and anti- Taenia crassiceps cysticerci vesicular fluid (anti-Tcra or anti-Tcra <30 kDa) [22].
• Human neurocysticercosis is caused by the establishment of Taenia solium cysticerci in the central nervous system [23].
• Analysis of the peripheral immune response in patients with neurocysticercosis: evidence for T cell reactivity to parasite glycoprotein and vesicular fluid antigens [24].
• The authors report the results obtained in 10 patients with cystic neurocysticercosis of the fourth ventricle who were treated with albendazole at a dosage of 15 mg/kg/day for 2 weeks [25].

Gene context of Neurocysticercosis

• Elevated concentrations of eotaxin and interleukin-5 in human neurocysticercosis [26].
• Interleukin-5 and interleukin-10 are major cytokines in cerebrospinal fluid from patients with active neurocysticercosis [27].
• Multiple neurocysticercosis showed higher levels of IL5/IL6 than single neurocysticercosis [23].
• Detection of glial fibrillary acidic protein and neurofilaments in the cerebrospinal fluid of patients with neurocysticercosis [28].
• Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy [29].

Analytical, diagnostic and therapeutic context of Neurocysticercosis

• SETTINGS: Patients admitted to neurologic wards in Lima, Peru. PATIENTS: Adult patients with active neurocysticercosis demonstrated by CT and Western blot (immunoblot) [2].
• We reviewed clinical, EEG, and CT findings of 203 patients with epilepsy due to neurocysticercosis [30].
• During the 3 years that the enzyme-linked immunoelectrotransfer blot (EITB) assay for the diagnosis of human cysticercosis has been in use at the Centers for Disease Control, 50 patients with both pathologically confirmed neurocysticercosis and computed tomographic (CT) or magnetic resonance imaging (MRI) scan results were identified [31].
• Specific Taenia crassiceps and Taenia solium antigenic peptides for neurocysticercosis immunodiagnosis using serum samples [32].
• To detect IgG antibodies to Taenia solium, a controlled double-blind study was conducted using 91 coded cerebrospinal fluid samples from patients with neurocysticercosis (NCC) and other neurologic disorders [33].

References